Company profile
MOLECULAR PARTNERS AG
NASDAQ:MOLNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MP-0250 | phase1_2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03136653 | phase1_2 | completed | 2017-05-23 | 2020-10-12 | Molecular Partners AG | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma |
| NCT05098405 | phase1 | terminated | 2021-10-11 | 2024-01-19 | Molecular Partners AG | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors |
| NCT03084926 | phase1 | completed | 2017-08-08 | 2021-12-13 | Molecular Partners AG | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors |
| NCT02194426 | phase1_2 | completed | 2014-07-01 | 2018-02-20 | Molecular Partners AG | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients |
| NCT04870164 | phase1 | terminated | 2020-11-18 | 2022-01-06 | Molecular Partners AG | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) |
FDA applications (0)
No records yet.